Welcome to the 4th Mitochondrial Dysfunction Drug Development Summit
The 4th Mitochondrial Dysfunction Drug Development Summit returns this November with a refined program that will enable you to accelerate the potential of mitochondrial-targeting technologies, acquire novel clinical intelligence, and tackle mitochondrial dysfunction in diverse populations to address the current challenges with patient stratification. From understanding the biological principles of mitochondrial diseases to bridging the gap between preclinical and clinical success, the 2024 Summit will highlight only the best academic and industry leaders’ achievements in discovery, translational research, and drug development over the past year.
-With a renewed program and focus, the 2024 summit will uncover mitochondrial dysfunction in diverse patient populations and develop higher efficacy targeting tactics for both primary mitochondrial diseases, and neurology, immunology, oncology, diabetes, and aging-related indications.
Join us this November as we bring together 60+ C-Level, Biologist, Preclinical, Translational, and Innovation-Scouting Leaders, including unmissable content highlights from Mitrix Bio, Mitochon Pharmaceuticals and Merck & Co
Join Your Peers To:
Address the limitations of current preclinical models for mitochondrial dysfunction to enhance translatability and facilitate clinical progression
Expand on your understanding of mitochondrial biology to highlight the complexity of mtDNA and uncover its link to disease mechanisms
Unlock mitochondrial targets linked with disease pathogenesis to unlock novel drug discovery opportunities alongside optimized biomarker validation to define endpoints for regulatory success
Unite patient advocacy groups, regulators, and healthcare technology assessors to build a whole ecosystem for tackling challenges with patient stratification
Our Previous Attendees:
What Your Peers Have to Say:
“Great discussions in a small group setting that enabled me the chance to meet people effectively transitioning from academic research into biotech therapeutic development.”
University of New England